Icon

NEXIUM IV (nda021689)- (EQ 20MG BASE/VIAL,EQ 40MG BASE/VIAL)

ESOMEPRAZOLE SODIUM ASTRAZENECA
EQ 20MG BASE/VIAL,EQ 40MG BASE/VIAL
Yes No
2015-May-27 Expired
None None
None No
NEXIUM I.V. is a proton pump inhibitor (PPI) indicated for the: • Short-term treatment of Gastroesophageal Reflux Disease (GERD) with erosive esophagitis (EE) in adults and pediatric patients 1 month to 17 years of age, as an alternative to oral therapy when oral NEXIUM is not possible or appropriate. • Risk reduction of rebleeding of gastric or duodenal ulcers following therapeutic endoscopy for acute bleeding gastric or duodenal ulcers in adults.
7 0 4
Total Other Developers None
Drugs with Suitability No
EQ 20MG BASE/VIAL ** ** - - -
EQ 40MG BASE/VIAL ** ** - - -
NDA Sales Available Total Generic Sales Available
No 2
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ***** ****** *** ***** ****** ******* *********** ****** **. *** - ***, *** & ***, **** ************* ***** *****, *. *. *****, ******** ****, ******** - ************* ******, ******* - ********** ********, *********, ********* ******, ***** (***) ***
****** ***** ****** ***** ****** ************ ******* *********** ****-***, **** **: *, ** ** **, ***, ** ** **, ****, *****, ***, ************ *******, ********** ******, **********, ********* ******, ***** (***) ***
****** ****** ******** ***** *************** ******* *********** **** **. ***/***-****** / **** **.***/****-*********** , *******-***** ******* , ****** -******, ******, *********, ******* ******, ***** (***) ***
****** ***** *** ****** ****** **** *****. **., ***. *********** ********** ******** *********** ****, ****** ********, ******, ****** ******, ***** (***) ***
****** ***** *** ****** ****** **** *****. **., ***. *** *********** ********** ******** *********** ****, ****** ********, ******, ****** ******, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.